Clinical trials: HTLV-1
Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
This study is for patients with lymphoproliferative malignancies that have progressed after receiving a previous treatment (relapsed) or are no longer responding to treatment (refractory).
- Conditions
- Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma
- Trial name
- NCT00481871
- Testing
- Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12
- Where
- 15 sites in United States
- Volunteers
- 119 people
- Sponsor
- Acrotech Biopharma Inc.
HTLV-1 Associated Myelopathy
A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM)
The objective of this study is to assess the efficacy and safety of KW-0761 after intravenous injections in subjects with HTLV-1 associated myelopathy (HAM) in Japan.
- Trial name
- NCT03191526
- Testing
- KW-0761 0.3 mg/kg IV
- Where
- 16 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Adult T-cell Leukemia, Lymphoma
A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)
To test the superiority of VCAP-AMP-VECP regimen over biweekly-CHOP in aggressive ATLL in terms of survival benefit.
- Trial name
- NCT00145002
- Testing
- VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis, biweekly-CHOP with G-CSF and intrathecal prophylaxis
- Where
- Japan
- Volunteers
- 130 people
- Sponsor
- Japan Clinical Oncology Group
Human T-cell Leukemia Virus Type 1 Infection
Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load
This is a study of the effect of raltegravir on human T-cell leukemia virus type 1 (HTLV-1) viral load in asymptomatic patients. The study will enroll 14 subjects for a period of 2 months of treatment and 1 month of followup.
- Trial name
- NCT01620736
- Testing
- Raltegravir
- Sponsor
- Washington University School of Medicine
HTLV-I-Associated Myelopathy
Safety and Efficiency Study of Valproic Acid In HAM/TSP
Reversible acetylation of the histone tails plays an important role in the control of specific gene expression. Mounting evidence has established that histone deacetylase inhibitors such as Valproic Acid (VPA)selectively induce…
- Trial name
- VALPROHAM (NCT00519181)
- Testing
- Valproic Acid
- Volunteers
- 19 people
- Sponsor
- University Hospital Pierre Zobda-Quitman
HTLV-I Infections
Electromiography Study in the Respiratory Muscle Training in Human Lymphotropic Virus Type 1
The main objective of the research will be to analyze, through surface electromyography, the impact of inspiratory muscle training before a supervised home training protocol in patients with human T-cell lymphotropic virus type 1…
- Trial name
- NCT03829709
- Testing
- Rehabilitation
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Universidade Metodista de Piracicaba
HTLV-1, Tropical Spastic Paraparesis
Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases
In this study the investigators are going to evaluate the efficacy pentoxifyline in HTLV-1 patients with neurological diseases: HAM/TSP or neurogenic bladder.
- Conditions
- HTLV-1, Tropical Spastic Paraparesis, Immune System Diseases, Physical Disability
- Trial name
- Pentox (NCT01472263)
- Testing
- Pentoxifylline
- Where
- Brazil
- Volunteers
- 48 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Lymphoma, Precancerous/Nonmalignant Condition
Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma
RATIONALE: Human T-cell lymphotropic virus type 1 (HTLV-1) can cause cancer. Zidovudine is an antiviral drug that acts against the human T-cell lymphotropic virus type 1.
- Trial name
- NCT00854581
- Testing
- PEG-interferon alfa-2b, Interferon alfa-2b, Valproic Acid
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Miami
Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment.
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma, HTLV-1 Infection, NK-Cell Lymphoma, Unclassifiable
- Trial name
- NCT03075553
- Testing
- Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Peripheral T-cell Lymphomas, Adult T-cell Leukemia/Lymphoma
Medical Access Program for Valemetostat Tosylate (DS 3201b) For The Treatment of Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)
Valemetostat tosylate demonstrates antitumour activity in patients with peripheral T-cell lymphomas (PTCL) with a manageable safety profile.
- Conditions
- Peripheral T-cell Lymphomas, Adult T-cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, Refractory Nodal T-follicular Helper Lymphoma
- Trial name
- NCT07862465
- Testing
- Valemetostat tosylate
- Sponsor
- Daiichi Sankyo
Acquired Immunodeficiency Syndrome, Blood Donors
Retrovirus Epidemiology Donor Study-II (REDS-II)
To conduct epidemiological, laboratory, and survey research on volunteer blood donors within the United States to ensure the safety and availability of the United States' blood supply.
- Conditions
- Acquired Immunodeficiency Syndrome, Blood Donors, Blood Transfusion, HIV Infections
- Trial name
- NCT00097006
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Paraparesis Spastic Tropical
Use Of Valproid Acid To Treat Tropical Spastic Paraparesis/HTLV-1-Associated Myelopathy (TSP/HAM)
Is the valproic acid efficacy to treat TSP/HAM
- Trial name
- NCT00681980
- Testing
- Valproic acid, costicosteroids, valproid acid plus corticosteroids
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo
T Cell Leukemia, Adult, Leukemia, Adult T-Cell
Ruxolitinib for Adult T-Cell Leukemia
Background: The human T-cell leukemia virus 1 (HTLV-1) causes adult T-cell leukemia (ATL). Infection does not immediately cause ATL, but it can develop over time.
- Conditions
- T Cell Leukemia, Adult, Leukemia, Adult T-Cell, T Cell Leukemia, HTLV I Associated
- Trial name
- NCT01712659
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoproliferation Induced by HTLV-1, HTLV-1 Adult T-cell Lymphoma / Leukemia
Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)
The purpose of this study is to evaluate the outcome (survival) of Adult T-cell leukemia / lymphoma (ATL) patients who receive or not specific treatment for their hemopathy (cohort 1) and the outcome (survival) of HTLV-1…
- Conditions
- Lymphoproliferation Induced by HTLV-1, HTLV-1 Adult T-cell Lymphoma / Leukemia, HTLV-1 Infection
- Trial name
- HTLV-OBS (NCT05237245)
- Where
- France
- Volunteers
- 69 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HTLV-1-associated Myelopathy
Rituximab for HTLV-1-associated Myelopathy
Neuroprotective or anti-inflammatory strategies are invaluable in HTLV-1-associated myelopathy due to its rapid progression. We evaluated the efficacy of rituximab in patients with HTLV-1-associated myelopathy.
- Trial name
- NCT04004819
- Testing
- Rituximab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Overactive Bladder Associated With HTLV-1
A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder
It's a double blind, placebo controlled study to assess the efficacy of Propantheline Bromide to treat overactive bladder (OAB) in HTLV 1 infected patients.
- Trial name
- NCT01640002
- Testing
- Propantheline Bromide
- Where
- Brazil
- Volunteers
- 42 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
HAM
Immunotherapy of Natural Killer(NK) Cells in Human T Lymphotropic Virus Type 1(HTLV-1) Associated Myelopathy(HAM)
HTLV-1 Associated Myelopathy is a chronic disease of the spinal cord, caused by a virus called human T lymphotropic virus type 1（HTLV-1）.
- Trial name
- NCT02961712
- Testing
- NK cells, amniotic epithelial cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Second Affiliated Hospital of Fujian Medical University
Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
Phase 1 (dose-escalation part): Investigate the tolerability and safety of ASTX660 in patients with r/r PTCL and r/r CTCL and determine the recommended dose (RD) for the Phase 2.
- Trial name
- NCT04362007
- Testing
- ASTX660
- Where
- Japan
- Volunteers
- 8 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
HTLV-1, Overactive Bladder Syndrome
Darifenacin x Parasacral Transcutaneous Electric Nerve Stimulation for OAB in Patients Infected With Human T-Lymphotropic Virus 1
In this study the investigators compare the parasacral transcutaneous electric nerve stimulation (PTENS) treatment with Darifenacin to improve OAB symptoms in patients infected with HTLV-1.
- Trial name
- NCT06616675
- Testing
- Darifenacin, Neuromodulation - Sacral nerve stimulation
- Where
- Brazil
- Volunteers
- 42 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
This phase II trial studies how well nivolumab works in treating patients with human T-cell leukemia virus (HTLV)-associated T-cell leukemia/lymphoma.
- Conditions
- Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection
- Trial name
- NCT02631746
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Pharmacogenomic Study
- Where
- 6 sites in United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)